For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO6296Ka&default-theme=true
RNS Number : 6296K Convatec Group PLC 15 April 2024
15 April 2024
Convatec Group Plc
("Convatec" or "the Company")
Annual Report and Accounts 2023 and Notice of Annual General Meeting
The Company announces that the following documents are available on its
website at www.convatecgroup.com (http://www.convatecgroup.com)
- Annual Report and Accounts 2023;
- Notice of Annual General Meeting; and
- Form of Proxy.
In compliance with Listing Rule 9.6.1, copies of these documents have been
submitted to the National Storage Mechanism and are available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .
Printed copies of these documents have also been sent to shareholders who have
requested hard copies.
Enquiries
Ria Banerjee, Group Deputy Company
Secretary
+44(0)7425 655 845
Cosec@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in advanced
wound care, ostomy care, continence and critical care, and infusion care. With
around 10,000 colleagues, we provide our products and services in almost 100
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Group revenues in 2022
were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more about Convatec, please visit
http://www.convatecgroup.com (http://www.convatecgroup.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ACSGCGDSBSBDGSU